{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:47:01Z","timestamp":1789325221301,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["21AA2007"],"award-info":[{"award-number":["21AA2007"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","doi-asserted-by":"crossref","award":["20H03907"],"award-info":[{"award-number":["20H03907"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10384-022-00969-2","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:08:55Z","timestamp":1670821735000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-6923","authenticated-orcid":false,"given":"Yohei","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"969_CR1","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"969_CR2","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","volume":"119","author":"R Varma","year":"2012","unstructured":"Varma R, Bressler NM, Su\u00f1er I, Lee P, Dolan CM, Ward J, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the bravo and cruise trials. Ophthalmology. 2012;119:2108\u201318.","journal-title":"Ophthalmology"},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the vibrant study. Ophthalmology. 2016;123:330\u20136.","journal-title":"Ophthalmology"},{"key":"969_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","volume":"158","author":"Y Ogura","year":"2014","unstructured":"Ogura Y, Roider J, Korobelnik J-F, Holz FG, Simader C, Schmidt-Erfurth U, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014;158:1032-8.e2.","journal-title":"Am J Ophthalmol"},{"key":"969_CR5","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (resolve study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399\u2013405.","journal-title":"Diabetes Care"},{"key":"969_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"969_CR7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","volume":"117","author":"MJ Elman","year":"2010","unstructured":"Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Diabetic Retinopathy Clinical Research Network, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-77.e35.","journal-title":"Ophthalmology"},{"key":"969_CR8","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2016;123:2376\u201385.","journal-title":"Ophthalmology"},{"key":"969_CR9","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik J-F, Vitti R, Li T, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization. Ophthalmology. 2015;122:1220\u20137.","journal-title":"Ophthalmology"},{"key":"969_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682-92.e2.","journal-title":"Ophthalmology"},{"key":"969_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s12325-020-01579-5","volume":"38","author":"M Inatani","year":"2021","unstructured":"Inatani M, Higashide T, Matsushita K, Miki A, Ueki M, Iwamoto Y, et al. Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial. Adv Ther. 2021;38:1116\u201329.","journal-title":"Adv Ther"},{"key":"969_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. The Lancet. 2019;394:1551\u20139.","journal-title":"The Lancet"},{"key":"969_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172:278.","journal-title":"JAMA Pediatr"},{"key":"969_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","volume":"137","author":"ST Berkowitz","year":"2019","unstructured":"Berkowitz ST, Sternberg P, Feng X, Chen Q, Patel S. Analysis of anti\u2013vascular endothelial growth factor injection claims data in US medicare part B beneficiaries from 2012 to 2015. JAMA Ophthalmol. 2019;137:921.","journal-title":"JAMA Ophthalmol."},{"key":"969_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","volume":"124","author":"R Parikh","year":"2017","unstructured":"Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology. 2017;124:352\u20138.","journal-title":"Ophthalmology"},{"key":"969_CR16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/QAD.0000000000003276","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye Lond Engl. 2022;36:1373\u20138.","journal-title":"Eye Lond Engl"},{"key":"969_CR17","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/ijerph19052548","volume":"19","author":"V Perrone","year":"2022","unstructured":"Perrone V, Dovizio M, Veronesi C, Citraro R, De Francesco A, Dell\u2019Orco S, et al. Retrospective analysis of the pharmaco-utilization of VEGF inhibitors and health care costs among patients with wet age-related macular degeneration and other ocular diseases in Italy. Int J Environ Res Public Health. 2022;19:2548.","journal-title":"Int J Environ Res Public Health"},{"key":"969_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10384-020-00802-8","volume":"65","author":"R Kawasaki","year":"2021","unstructured":"Kawasaki R, Bauer M, Bezlyak V, Ogura Y. Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: a retrospective analysis of claims data from the Japan medical data center database. Jpn J Ophthalmol. 2021;65:215\u201326.","journal-title":"Jpn J Ophthalmol"},{"key":"969_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.ophtha.2007.11.015","volume":"115","author":"R Kawasaki","year":"2008","unstructured":"Kawasaki R, Wang JJ, Ji G, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115:1376-81.e2.","journal-title":"Ophthalmology"},{"key":"969_CR20","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1167\/iovs.09-4453","volume":"51","author":"M Yasuda","year":"2010","unstructured":"Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the hisayama study. Investig Opthalmology Vis Sci. 2010;51:3205.","journal-title":"Investig Opthalmology Vis Sci."},{"key":"969_CR21","first-page":"190","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138.","journal-title":"JMA J"},{"key":"969_CR22","unstructured":"Ministry of Health, Labour and Welfare, Japan. Universal health insurance system. https:\/\/www.mhlw.go.jp\/bunya\/iryouhoken\/iryouhoken01\/dl\/01a.pdf. Accessed 7 Sep 2022 (in Japanese)"},{"key":"969_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16:791\u2013801.","journal-title":"Stat Med"},{"key":"969_CR24","unstructured":"Ministry of Health, Labour and Welfare, Japan. NDB open data. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html. Accessed 7 Sep 2022 (in Japanese)"},{"key":"969_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/jdi.12929","volume":"10","author":"M Sugimoto","year":"2019","unstructured":"Sugimoto M, Tsukitome H, Okamoto F, Oshika T, Ueda T, Niki M, et al. Clinical preferences and trends of anti-vascular endothelial growth factor treatments for diabetic macular edema in Japan. J Diabetes Investig. 2019;10:475\u201383.","journal-title":"J Diabetes Investig."},{"key":"969_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10384-016-0481-x","volume":"61","author":"Y Ogura","year":"2017","unstructured":"Ogura Y, Shiraga F, Terasaki H, Ohji M, Ishida S, Sakamoto T, et al. Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists. Jpn J Ophthalmol. 2017;61:43\u201350.","journal-title":"Jpn J Ophthalmol"},{"key":"969_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10384-019-00685-4","volume":"63","author":"Y Ogura","year":"2019","unstructured":"Ogura Y, Kondo M, Kadonosono K, Shimura M, Kamei M, Tsujikawa A. Current practice in the management of branch retinal vein occlusion in Japan: survey results of retina specialists in Japan. Jpn J Ophthalmol. 2019;63:365\u201373.","journal-title":"Jpn J Ophthalmol"},{"key":"969_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.16-19963","volume":"57","author":"J Fujimoto","year":"2016","unstructured":"Fujimoto J, Swanson E. The development, commercialization, and impact of optical coherence tomography. Investig Opthalmol Vis Sci. 2016;57:1\u201313.","journal-title":"Investig Opthalmol Vis Sci."},{"key":"969_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663\u201371.","journal-title":"Ophthalmology"},{"key":"969_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43-58.e1.","journal-title":"Am J Ophthalmol"},{"key":"969_CR31","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying G, Grunwald JE, Fine SL, CATT Research Group, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"969_CR32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/bjo.85.10.1153","volume":"85","author":"Y Oshima","year":"2001","unstructured":"Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153\u20137.","journal-title":"Br J Ophthalmol"},{"key":"969_CR33","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.ophtha.2006.02.052","volume":"113","author":"R Kawasaki","year":"2006","unstructured":"Kawasaki R, Wang JJ, Rochtchina E, Taylor B, Wong TY, Tominaga M, et al. Cardiovascular risk factors and retinal microvascular signs in an adult japanese population: the funagata study. Ophthalmology. 2006;113:1378\u201384.","journal-title":"Ophthalmology"},{"key":"969_CR34","unstructured":"Ministry of Health, Labour and Welfare, Japan. National health and nutrition survey (2019). https:\/\/www.mhlw.go.jp\/content\/10900000\/000687163.pdf. Accessed 9 Apr 2022 (in Japanese)."},{"key":"969_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"969_CR36","first-page":"1150","volume":"116","author":"K Takahashi","year":"2012","unstructured":"Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. Treatment guidelines for age-related macular degeneration. Nippon Ganka Gakkai Zasshi. 2012;116:1150\u20135 (in Japanese).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"969_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: An evidence-based systematic review. Ophthalmology. 2010;117:1094-101.e5.","journal-title":"Ophthalmology"},{"key":"969_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.oret.2018.11.014","volume":"3","author":"TA Moulin","year":"2019","unstructured":"Moulin TA, Adjei Boakye E, Wirth LS, Chen J, Burroughs TE, Vollman DE. Yearly treatment patterns for patients with recently diagnosed diabetic macular edema. Ophthalmol Retina. 2019;3:362\u201370.","journal-title":"Ophthalmol Retina."},{"key":"969_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"969_CR40","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32:1010\u201320.","journal-title":"Eye (Lond)"},{"key":"969_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","volume":"165","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, et al. Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;165:1\u20136.","journal-title":"Am J Ophthalmol"},{"key":"969_CR42","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/bjophthalmol-2014-305275","volume":"99","author":"M Hosokawa","year":"2015","unstructured":"Hosokawa M, Shiraga F, Yamashita A, Shiragami C, Ono A, Shirakata Y, et al. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99:1087\u201391.","journal-title":"Br J Ophthalmol"},{"key":"969_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/jop.2014.0160","volume":"31","author":"M Gharbiya","year":"2015","unstructured":"Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V. Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther. 2015;31:357\u201362.","journal-title":"J Ocul Pharmacol Ther"},{"key":"969_CR44","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1167\/iovs.14-14610","volume":"55","author":"M Hata","year":"2014","unstructured":"Hata M, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ooto S, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55:7874\u201380.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"969_CR45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139.","journal-title":"Ophthalmology"},{"key":"969_CR46","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Writing Committee for the Diabetic Retinopathy Clinical Research Network, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314:2137.","journal-title":"JAMA"},{"key":"969_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta25380","volume":"25","author":"P Hykin","year":"2021","unstructured":"Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, et al. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technol Assess. 2021;25:1\u2013196.","journal-title":"Health Technol Assess"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00969-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:58:12Z","timestamp":1744210692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00969-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00969-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Hashimoto, None; A. Okada, None; H. Matsui, None; H. Yasunaga, None; M. Aihara, Grants or contracts (Santen, Senju, Alcon, Novartis, Pfizer, Kowa, Otsuka, Wakamoto, Johnson & Johnson, Glaukos, TOMEY, Ono, CREWT Medical Systems, Sato), Consulting fees (Santen, Senju, Alcon, Pfizer, Kowa, Otsuka, Wakamoto, HOYA, Glaukos, IRIDEX, Astellas), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Novartis, Pfizer, Kowa, Otsuka, Johnson & Johnson, HOYA, Glaukos, TOMEY, IRIDEX, CREWT Medical Systems, Canon, ZEISS, Sato), Participation on a Data Safety Monitoring Board or Advisory Board (Santen, Senju, HOYA, Kowa), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Kowa, Santen); R. Obata, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Bayer, Santen, Senju, Alcon).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}